Since BRAFV600E oncogene is the most common mutation found in thyroid cancer and is associated with radioiodine refractory disease [29, 30], we examined NIS protein levels in BRAFV600E expressing cells co-treated with TGF-β and inhibitors in the presence or absence of Apigenin. This evidence concerns the gene SLC5A5 and thyroid cancer.